SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trial

— KEYSTROKE  

Official title:

KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03546582
• Other study ID #: RTOG 3507
• Status: Recruiting
• Phase: Phase 2
• Start date: November 14, 2018
• Est. completion date: July 2029

Study information

• Verified date: June 2023
• Source: RTOG Foundation, Inc.
• Contact: Stuart J. Wong, MD
• Phone: 414-805-4621
• Email: swong[@]mcw.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial with a safety run-in component will evaluate whether the addition of pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the progression-free survival for patients with recurrent or new second primary Head and Neck Squamous Cell Carcinoma (HNSCC).

Description:

Safety Run-In:

To evaluate the safety of the addition of pembrolizumab (anti PD-1 immunotherapy) to re-irradiation with SBRT for patients with recurrent or new second primary head and neck squamous cell carcinoma (HNSCC).

Phase II:

To compare progression-free survival (PFS) for patients with recurrent or new second primary head and neck squamous cell carcinoma with SBRT re-irradiation with or without pembrolizumab.

OUTLINE:

Safety Run-In: Patients receive SBRT over 2 weeks and then receive pembrolizumab every 3 weeks for up to 2 years.

Phase II: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive SBRT over 2 weeks and then receive pembrolizumab every 3 weeks for up to 2 years.

ARM II: Patients receive SBRT over 2 weeks. Arm II patients who experience progressive disease within 2 years after the start of SBRT will be allowed to cross over to receive pembrolizumab for up to 2 years.

After the completion of study treatment, patients are followed up every 6 months for 3 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 102
• Est. completion date: July 2029
• Est. primary completion date: July 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologically (histologically or cytologically) confirmed diagnosis of locoregional recurrent or any new primary squamous cell carcinoma of the head and neck (including of the nasopharynx or paranasal sinus) that is not amenable to curative resection.

• Patients for whom curative resection would be medically contraindicated and/or would impose excessive surgical risk are eligible.

• Patients who are medically and surgically resectable but for whom surgery would be associated with undue surgical morbidity are eligible.

• For purposes of this protocol, undue surgical morbidity would include total glossectomy; carotid artery resection; laryngectomy or pharyngolaryngectomy; and major ablative resection requiring free flap reconstruction. Patients with primary tumors that can be resected without the forgoing are ineligible.

• The principal investigators are available to review these criteria on a case by case basis if helpful to the enrolling institution.

A new primary HNSCC is defined where any one of the following criteria are met:

• Metachronous invasive SCC developing = 6 months after an index HNSCC, more than 3 cm from the index lesion;

• SCC developing in the same region as the index SCC if = 36 months after the index diagnosis and if within 3 cm of a site where disease was completely resected or complete response was documented;

• New SCC that is cytologically or molecularly distinct from index SCC (e.g. new HPV negative SCC with prior index SCC that was HPV positive).

• Tumor tissue testing for p16 status is required for base of tongue, soft palate, and tonsil cancer. If a p16 testing has been previously performed on an oropharynx cancer that has recurred, then repeat testing for p16 status is not required. Participants whose first cancer was an unknown primary must have p16 testing from either the new primary tumor or the recurrent cancer.

• Prior radiotherapy (RT) to the head and neck (30 Gy minimum)

• Disease must be limited to a single site or adjacent sites that can be treated in a single contiguous target volume for which the maximum total tumor dimension (GTV) must be <7.5cm. Examples of eligible patients include:

1. A primary site recurrence in the oropharynx with a concurrent level 2 nodal mass, or a laryngeal recurrence with a level 3 nodal mass

2. Multiple nodes in the same (level 2) or adjacent nodal levels (levels 2 and 3)

3. Skull base recurrence with a lateral pharyngeal or high level 2 node

Note: These cases will be eligible provided that the maximum total tumor dimension is <7.5cm. For cases in which a tumor biopsy was performed and there is a biopsy/tumor debulking bed adjacent to the gross residual disease, all of the preoperative radiographic abnormalities must be included in the GTV and meet the <7.5cm maximal dimension criteria to meet eligibility.

Note: Patients who meet these criteria only after surgical removal of a portion of the patient's disease (e.g. removal of level 4 nodal mass in a patient with a tongue base primary; or of a contralateral nodal mass in an N2c patient) are ineligible.

• Patients who have undergone a recent biopsy (e.g. incisional) are eligible. Any preceding surgical procedure beyond a biopsy (e.g. debulking) must be reviewed as follows:

• Patients rendered free of gross disease are not eligible.

• Patients with gross residual disease postoperatively, must be reviewed by the Surgical Co-PI for determination of eligibility.

• Patients eligible for study must have cutaneous wounds healed for 4-6 weeks prior to the initiation of SBRT.

• History/physical examination within 56 days prior to entry

• Examination by a Radiation Oncologist and Medical Oncologist within 56 days prior to entry; [Note: Baseline dental assessment is strongly recommended prior to start of therapy but is not required for eligibility]

• Contrast enhanced CT or MRI, of the tumor and neck within 56 days prior to entry.

• Chest CT scan or full body PET/CT within 56 days prior to entry; patients with equivocal pulmonary nodules that are < 1.5 cm, that cannot be safely biopsied, or that are negative on PET/CT imaging are eligible.

• Zubrod Performance Status of 0-1 within 28 days prior to entry.

• Age = 18

• Trial is open to all genders

• Hematologic: Absolute neutrophil count (ANC) = 1,500 cells/mm3, Platelets = 100,000 cells/mm3, Hemoglobin = 9 g/dL

• Hepatic: Total bilirubin = 1.5 x ULN OR Direct bilirubin = ULN for subjects with total bilirubin levels > 1.5 x ULN, AST (SGOT) and ALT (SGPT) = 2.5 x ULN

• Creatinine = 1.5 x ULN, OR measured or calculated creatinine clearance > 60 mL/min for subject with creatinine levels > 1.5 x institutional ULN [NOTE: Calculated creatinine per institutional standard; GFR may be used in place of creatinine or CrCl]

• Coagulation: International normalized ratio (INR), OR prothrombin time (PT), and Activated partial thromboplastin time (aPTT): =1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants

• Negative serum pregnancy test within 14 days prior to entry for women of childbearing potential. (Note: A pregnancy test must be repeated within 3 days prior to the administration of the first dose of pembrolizumab)

• The patient or legally authorized representative must provide study-specific informed consent prior to study entry.

Exclusion Criteria:

• Distant metastases.

• Tumors that involve more than 180 degrees of the carotid artery that directly communicates with the skin or mucosal surface (e.g., if the tumor communicates with either external air outside of the skin, or internal air inside mucosal surfaces) on diagnostic CT or MRI of the neck within 56 days prior to entry.

Note: Tumors that involve >180 degrees of the carotid, and even those that fully encase the carotid artery are eligible if they do not meet the above criterion. Investigators should email the Study Principal Investigators to review any cases whose eligibility due to carotid encasement are unclear.

Investigators are encouraged to review the CT simulation imaging and ensure that tumor progression has not occurred whereby patients who were initially eligible based on diagnostic imaging, would be rendered ineligible based on CT simulation imaging (e.g. tumor size >7.5cm, skin involvement, >180 degrees of carotid encasement by tumor). If this does occur, the patient should be removed from the study and the Radiation Oncology Co-PIs should be notified via email. Note: It is strongly recommended that CT simulation be performed prior to entry.

• Patients with gross skin involvement (i.e. tumor ulceration through the skin) are excluded. Patients with tumor approaching the skin but in which the overlying skin remains intact are eligible, providing that planning constraints can be achieved without the use of bolus.

• Disease that requires two or more discontiguous target volumes will be ineligible. Examples of such cases include:

• Bilateral nodal targets

• Level 2 and level 4 nodes

• An oropharyngeal recurrence with a low level 4 node;

• Patients for whom the maximal total tumor dimension (GTV) is >7.5cm

• Prior radiation to primary tumor within 6 months of entry

• Prior systemic therapy, investigational agent or investigational device within 28 days of start of study treatment.

• Surgical resection of the qualifying cancer is not permitted. (Patients who have undergone biopsies are eligible). Patients without radiographically apparent gross tumor are ineligible. For cases where an operation more extensive than a biopsy was performed but radiographically apparent gross residual tumor remains, will be reviewed by the Surgical Co-PI for determination of eligibility.

• No concurrent treatment with other investigational agent or investigational device.

• Prior therapy with a checkpoint inhibitor (eg anti-CTLA-4, anti-PD-1 or anti-PD-L1 therapy).

• Patients with immunodeficiency, or receiving systemic steroid, or any form of immunosuppressive therapy at the time of registration (e.g. history of human immunodeficiency virus - HIV). Use of physiologic doses corticosteroids may be approved with consultation with study chairs.

• Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxin, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency etc.) is not considered a form of systemic therapy

• Known active hepatitis B (positive test for virus surface antigen - HBsAg) or hepatitis C virus (e.g. positive HCV RNA qualitative test).

• History of (non-infectious) pneumonitis that required steroids or current pneumonitis.

• Treatment with a live vaccine within 30 days of entry. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines and are not allowed

• Unstable angina and or congestive heart failure requiring hospitalization in the last 6 months.

• Transmural myocardial infarction within the last 6 months.

• Active bacterial or fungal infection requiring intravenous antibiotic at the time of registration; Note: If the infection resolves and the patient is on p.o. and still within, the required registration timeframe, then the patient is eligible

• Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of entry.

• Other significant medical, surgical or psychiatric conditions or requirements for any medication or treatment that in the opinion of the investigator may interfere with compliance, make administration of anti-PD-L1 therapy hazardous, or obscure interpretation of adverse events (AEs), such as a condition associated with frequent diarrhea.

• Pregnancy, nursing females, or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Squamous Cell Carcinoma (HNSCC)
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• Pembrolizumab
Anti-PD-1 targeted immunotherapy

Radiation:
• Stereotactic Body Radiation Therapy (SBRT)
High-precision radiotherapy

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	Centre Hospitalier de l'université de Montréal	Montréal	Quebec
Canada	McGill University	Montréal	Quebec
Canada	CHU de Quebec - Universite Laval	Québec	Quebec
United States	Boston Medical Center	Boston	Massachusetts
United States	University of Cincinnati Cancer Center - UC Medical Center	Cincinnati	Ohio
United States	Cleveland Clinic	Cleveland	Ohio
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	Ohio State University	Columbus	Ohio
United States	University of Texas Southwestern	Dallas	Texas
United States	Henry Ford Hospital	Detroit	Michigan
United States	Penn State Milton S. Hershey Medical Center	Hershey	Pennsylvania
United States	Northwell Health	Lake Success	New York
United States	University of Louisville, James Graham Brown Cancer Center	Louisville	Kentucky
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania
United States	University of Pittsburgh Medical Center Shadyside	Pittsburgh	Pennsylvania
United States	Washington University St. Louis	Saint Louis	Missouri
United States	Moffitt Cancer Center	Tampa	Florida
United States	University of Arizona Cancer Center - North Campus	Tucson	Arizona
United States	Cleveland Clinic - Weston	Weston	Florida

Sponsors (2)

Lead Sponsor	Collaborator
RTOG Foundation, Inc.	Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS)	The time from randomization to the first documented progressive disease (PD) per RECIST 1.1 or death due to any cause, whichever comes first.	Assessed up to 5 years
Secondary	Overall Survival (OS)	The time from randomization to death due to any cause.	Assessed up to 5 years